Clinical trials: Multiple Primary Neoplasm
Glaucoma, Primary Open Angle, Ocular Hypertension
Exploratory Trial to Evaluate the Efficacy and Safety of D565H Twice Daily Versus D565 Once Daily
Exploratory trial to evaluate the efficacy and safety of D565H twice daily versus D565 once daily.
- Trial name
- NCT03067415
- Testing
- D565H(Latanoprost 25㎍/㎖), D565(Latanoprost 50㎍/㎖)
- Where
- South Korea
- Volunteers
- 98 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Myelofibrosis
Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in the Treatment of Myelofibrosis With Myeloid Metaplasia
Defects in the apoptotic process can lead to the onset of cancer by allowing cells to grow unchecked when an oncogenic signal is present.
- Trial name
- NCT00360035
- Testing
- Obatoclax mesylate (GX15-070MS)
- Where
- 7 sites in United States, Canada
- Volunteers
- 22 people
- Sponsor
- Gemin X
Antifungal Prophylaxis of Invasive Fungal Infections
Voriconazole Versus Itraconazole In Primary Prophylaxis Of Invasive Fungal Infection (IFI) In Subjects With Allogeneic Hematopoietic Stem Cell Transplants (HSCT)
Study is to compare antifungal prophylaxis of Voriconazole and Itraconazole in subjects who have had a Stem Cell Transplant. The success of the end point will be measured using evidence of Infection, drug compliance and survival.
- Trial name
- IMPROVIT (NCT00289991)
- Testing
- Itraconazole, Vfend - voriconazole
- Where
- 49 sites in Canada, Czechia and 10 more
- Volunteers
- 489 people
- Sponsor
- Pfizer
Primary Lung Cancer, Benign Lung Disease
SP Thoracic IDE Study
To confirm the safety and performance of the da Vinci SP Surgical System, Instruments and Accessories in pulmonary lobectomy, and in thymectomy procedures.
- Conditions
- Primary Lung Cancer, Benign Lung Disease, Thymoma, Myasthenia Gravis
- Trial name
- NCT05150210
- Testing
- Robotic-Assisted Surgery
- Where
- 6 sites in United States
- Volunteers
- 32 people
- Sponsor
- Intuitive Surgical
Migraine
Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Participants With Migraine
A migraine attack is a moderate or severe headache that usually occurs on one side of the head and is often accompanied by throbbing, sensitivity to light, sensitivity to sound, nausea, or other symptoms.
- Trial name
- ATO ACUTE (NCT06241313)
- Testing
- Atogepant
- Where
- 149 sites in Belgium, China and 13 more
- Volunteers
- 2,158 people
- Sponsor
- AbbVie
Infections, Meningococcal
Study to Evaluate the Long-term Antibody Persistence of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine (GSK134612) Versus Mencevax ACWY in Healthy Adolescents and Adults and Booster Response to MenACWY-TT Vaccine Administered at 10 Years Post-primary Vaccination
The purpose of this study is to evaluate the long-term antibody persistence from 6, 7, 8, 9 to 10 years post-administration of MenACWY-TT conjugate vaccine as compared to Mencevax ACWY when given to healthy subjects 11 to 55…
- Trial name
- NCT01934140
- Testing
- Meningococcal vaccine GSK134612
- Where
- 2 sites in Philippines
- Volunteers
- 311 people, healthy volunteers welcome
- Sponsor
- Pfizer
Hip Osteoarthritis
Assess the Mid-term Performance of the Mpact Cup in Subjects Requiring Total Hip Arthroplasty
Monitor the performance of the Mpact cup in the treatment of patients with hip joint disease requiring a total hip replacement.
- Trial name
- NCT03897595
- Testing
- MPact Cup
- Where
- 5 sites in United States
- Volunteers
- 187 people, healthy volunteers welcome
- Sponsor
- Medacta USA
Stage III Breast Cancer, Stage IV Breast Cancer
Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs
The primary objective of this study, sponsored by Travera in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations using…
- Conditions
- Stage III Breast Cancer, Stage IV Breast Cancer, Stage III Lung Cancer, Stage IV Lung Cancer
- Trial name
- NCT04985357
- Sponsor
- Travera Inc
Primary Open-angle Glaucoma (POAG), Ocular Hypertension
Study of SHP639 Eye Drops in Adults With High Eye Pressure or Primary Open-angle Glaucoma
Safety and tolerability of three different concentrations (0.1%, 03%, 0.6%) of the investigational SHP639 eye drops will be evaluated in participants with high eye pressure or primary open-angle glaucoma.
- Trial name
- NCT03131167
- Testing
- SHP639 (n=60)
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Shire
Primary Open Angle Glaucoma (POAG)
Study of CyPass Implantation In Patients With Open Angle Glaucoma Refractory to Single or Multi-agent Topical Therapy
The purpose of this study is to evaluate the safety and effectiveness of CyPass implantation as a stand-alone therapy for lowering intraocular pressure (IOP) in patients with primary open angle glaucoma (POAG) who have failed at…
- Trial name
- DUETTE (NCT01166659)
- Testing
- CyPass Micro-Stent
- Volunteers
- 48 people
- Sponsor
- Transcend Medical, Inc.
Central Nervous System (CNS) Lesions, Brain Metastases
Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent
This Phase 2 clinical trial will study RVP-001, a new manganese-based MRI contrast agent, in people who are known to have gadolinium-enhancing central nervous system (CNS) lesions, for example brain tumors or multiple sclerosis.
- Conditions
- Central Nervous System (CNS) Lesions, Brain Metastases, Brain Neoplasms, Brain Neoplasms, Benign
- Trial name
- NCT06322342
- Testing
- RVP-001
- Where
- 5 sites in United States
- Volunteers
- 18 people
- Sponsor
- Reveal Pharmaceuticals Inc.
Parkinson's Disease (PD), Multiple System Atrophy (MSA)
[18F]ACI-15916 PET in α-synucleinopathies
The goal of this clinical trial is to test whether we can reliably and safely measure the accumulation of pathological protein α-synuclein [involved in some diseases such as Parkinson's disease, Lewy body dementia and Multiple…
- Conditions
- Parkinson's Disease (PD), Multiple System Atrophy (MSA), Dementia With Lewy Bodies (DLB)
- Trial name
- NCT06891703
- Testing
- [18F]ACI-15916
- Where
- Sweden
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- AC Immune SA
Multiple System Atrophy, Parkinson Variant
A Trial of ONO-2808 in Participants With the Parkinsonian Subtype of Multiple System Atrophy (MSA-P)
The main goal of this clinical trial is to learn if ONO-2808 works to treat adults with the Parkinsonian subtype of Multiple System Atrophy (MSA-P).
- Trial name
- NCT07825402
- Testing
- ONO-2808
- Volunteers
- 486 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Migraine
AMG 334 20160172 Pediatric Migraine PK Study.
AMG 334 20160172 Pediatric Migraine PK Study.
- Trial name
- NCT03499119
- Testing
- AMG 334 Dose 1, AMG 334 Dose 2, AMG 334 Dose 3
- Where
- 14 sites in United States
- Volunteers
- 53 people
- Sponsor
- Amgen
Pinnacle Metal-on-Metal, Revised Pinnacle Metal-on-Metal
Pinnacle Metal-on-Metal 522 Post-Market Surveillance Study
The purpose of this clinical study is to evaluate blood metal ion levels as a function of time of implantation for the Pinnacle Acetabular MoM system.
- Conditions
- Pinnacle Metal-on-Metal, Revised Pinnacle Metal-on-Metal, Adverse Local Tissue Reaction, Metal Ions
- Trial name
- NCT01828801
- Testing
- Pinnacle Metal-on Metal
- Where
- 8 sites in United States
- Volunteers
- 276 people
- Sponsor
- DePuy Orthopaedics
Multiple System Atrophy
A Phase 2 Study of YA-101 in Patients With Multiple System Atrophy
This is a Phase 2, double-blind, placebo-controlled, multi-center, Phase II, dose escalation study to evaluate the safety, tolerability, pharmacokinetics and efficacy of Ya-101 in subjects with multiple system atrophy.
- Trial name
- NCT06848231
- Testing
- YA-101
- Where
- 9 sites in United States, Japan and 1 more
- Volunteers
- 75 people
- Sponsor
- Dasher Neuroscience Inc.
Osteoarthritis
52 Week, International, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Clinical Trial to Compare Retention on Treatment, Safety, Tolerability & Efficacy of Lumiracoxib 100 mg od, Lumiracoxib 100 mg Bid & Celecoxib 200 mg od in Pts With Primary OA of Hip, Knee, Hand or Spine
This trial will compare the retention on treatment (based on the rate of patients staying on treatment for 1 year) of patients suffering from primary osteoarthritis using two different doses of lumiracoxib (100 mg od or 100 mg…
- Trial name
- NCT00145301
- Testing
- Lumiracoxib
- Where
- Germany
- Volunteers
- 3,036 people
- Sponsor
- Novartis
Fallopian Tube Cancer, Ovarian Cancer
Phenoxodiol Combined With Either Cisplatin or Paclitaxel in Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
RATIONALE: Drugs used in chemotherapy, such as cisplatin and paclitaxel, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00091377
- Testing
- cisplatin, paclitaxel, phenoxodiol
- Where
- 2 sites in United States, Australia
- Volunteers
- 65 people
- Sponsor
- MEI Pharma, Inc.
Hepatocellular Carcinoma, Renal Cell Carcinoma
Study of ACC-1898 in Adult Participants With Advanced Solid Tumors
This is a research study of an experimental drug called ACC-1898. ACC-1898 is an oral tyrosine kinase inhibitor (TKI) that blocks several proteins kinases which may help cancer cells grow and spread.
- Conditions
- Hepatocellular Carcinoma, Renal Cell Carcinoma, Thyroid Carcinoma, Medullary, Thyroid Carcinoma Primary Differentiated
- Trial name
- NCT07252661
- Testing
- ACC-1898
- Volunteers
- 40 people
- Sponsor
- AccSalus Biosciences, Inc.
Head and Neck Cancer
Photodynamic Therapy in Treating Patients With Recurrent, Refractory, or Second Primary Head and Neck Cancer That Cannot Be Treated With Surgery or Radiation Therapy
RATIONALE: Photodynamic therapy uses light and drugs that make cancer cells more sensitive to light to kill tumor cells. This may be an effective palliative treatment for head and neck cancer.
- Trial name
- NCT00003856
- Testing
- temoporfin
- Where
- 7 sites in United States
- Volunteers
- 75 people
- Sponsor
- Quintiles, Inc.